BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang ML, Zhou QL, Chen EQ, Du LY, Yan LB, Bai L, He M, Tang H. Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg Seroconversion. Viral Immunol 2016;29:332-42. [PMID: 27104358 DOI: 10.1089/vim.2016.0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Shang J, Liu H, Wen Q, M Ise R, Tu Y, Bai L, Tang H. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Int J Infect Dis 2021;105:626-31. [PMID: 33722684 DOI: 10.1016/j.ijid.2021.03.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang Y, Wang YT, Luo JX, Hu XY, Yang F, Lin W, Liang X, Zhao BJ, Zhang S, Chen YY. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20-30 Times the ULN). Evid Based Complement Alternat Med 2019;2019:7260369. [PMID: 30949222 DOI: 10.1155/2019/7260369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat 2017;24 Suppl 1:29-35. [PMID: 29082652 DOI: 10.1111/jvh.12794] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]